What Pharma Investors Need to Know About Pfizer's Latest Disaster - Motley Fool

What Pharma Investors Need to Know About Pfizer's Latest Disaster  Motley Fool

Xeljanz recently ran into a safety problem, but investors aren't sure if this will open doors for similar drugs in development, or slam them shut.



Comments

Post a Comment

Popular posts from this blog

Celgene Corporation Announces POMALYST® Granted Breakthrough Therapy Designation from FDA for HIV-Positive and Negative Kaposi Sarcoma - Global Banking And Finance Review

Celgene Corporation Announces POMALYST® Granted Breakthrough Therapy Designation from FDA for HIV-Positive and Negative Kaposi Sarcoma    Global Banking And Finance Review Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to ...
Read more